Market Research Logo

Global Huntington's Disease Therapeutics Market 2017-2021

Global Huntington's Disease Therapeutics Market 2017-2021

About Huntington’s Disease Therapeutics

HD is an inherited condition that leads to destruction of nerve cells or neurons. The damage to nerve cells usually causes change in personality, mood swings, irritability and altered behavior. The global HD therapeutics market was witnessing a high unmet demand for disease modifying drug, in the presence of only one approved therapy, Xenazine, and the off-label use of various different therapeutics. The introduction of AUSTEDO in the market will have a significant impact on the market growth, thereby changing the market dynamics.

Technavio’s analysts forecast the global huntington’s disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global huntington’s disease therapeutics market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Huntington’s Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries
Other prominent vendors
  • Intellect Neurosciences
  • Horizon Pharma
  • Sangamo Therapeutics
  • Vertex Pharmaceuticals
Market driver
  • Early onset of disease symptoms, increases the demand for HD therapeutics
  • For a full, detailed list, view our report
Market challenge
  • Increase in alternative programs for management of mental disorders
  • For a full, detailed list, view our report
Market trend
  • Advances in biomedical sciences
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Huntington’s Disease Therapeutics Market 2017-2021

Technavio recognizes the following companies as the key players in the global huntington’s disease therapeutics market: F. Hoffmann-La Roche, H. Lundbeck, Prana Biotechnology, and Teva Pharmaceutical Industries.

Other Prominent Vendors in the market are: Intellect Neurosciences, Horizon Pharma, Sangamo Therapeutics, and Vertex Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is advances in biomedical sciences. In the past few decades, the advancement in science and introduction of nanotechnologies in the global pharmaceutical market, have revolutionized the development of medicines. With better understanding of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy, thus producing disease modifying drugs.”

According to the report, one driver in the market is early onset of disease symptoms, increases the demand for HD therapeutics. The prevalence rate of HD is equal in both males and females, and the disease affects humans of all ethnic and racial groups. The disease symptoms first appear in the mid-life, between the ages of 25-45 years. In some cases, the disease symptoms may appear as early as the age of two years in children. Children suffering from HD rarely live to their adulthood. Since, the etiology of HD disease is genetic in origin, there are always 50/50 chances of inheriting the mutated gene from the affected parents.

Further, the report states that one challenge in the market is increase in alternative programs for management of mental disorders. The currently available HD therapeutics are unsuccessful in eliminating the symptoms of most of the mental disorders and are known to cause severe side effects such as weight gain, sedation, prolongation of the corrected QT (QTc) interval, and fatal blood dyscrasias. Thus, demonstrating a high unmet need for the development of novel therapeutics that can fill the gap between diagnosis and adherence to drug therapies. This, in turn, has led to the high adoption of alternative programs for the management of HD.

Companies Mentioned

F. Hoffmann-La Roche, H. Lundbeck, Prana Biotechnology, and Teva Pharmaceutical Industries.

Other Prominent Vendors in the market are: Intellect Neurosciences, Horizon Pharma, Sangamo Therapeutics, and Vertex Pharmaceuticals.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Parts of brain affected by HD
  • HD: An introduction
    • Table Key facts about HD
    • Table Prevalence and incidence of HD
    • Table Neurotransmitter involved in pathogenesis of HD
  • Market landscape
    • Market overview
      • Table Market snapshot
    • Market size and forecast
      • Table Global HD therapeutics market 2016-2021 ($ millions)
      • Table Opportunity analysis of global HD therapeutics market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline
    • Table Pipeline landscape based on number of molecules 2016
    • Table HD: Key clinical trials
  • Market segmentation by drug-class
    • Market scenario by drug-class
      • Table Segmentation of global HD therapeutics market by drug-class
      • Table Global HD therapeutics market share by drug-class
    • Antidopaminergics
      • Table Antidopaminergics used in HD
      • Table Uses and side-effects of antidopaminergics
      • Table Global HD therapeutics market by antidopaminergics 2016-2021 ($ millions)
      • Table Pharmacologic approach for the treatment of chorea
    • Anticonvulsants
      • Table Anticonvulsants used in HD
      • Table Uses and side-effects of anticonvulsants
      • Table Global HD therapeutics market by anticonvulsants 2016-2021 ($ millions)
    • Antipsychotics
      • Table Antipsychotics used in HD
      • Table Uses and side-effects of antipsychotics
      • Table Global HD therapeutics market by antipsychotics 2016-2021 ($ millions)
    • Antidepressants
      • Table Symptoms of depression associated with HD
      • Table Global HD therapeutics market by antidepressants 2016-2021 ($ millions)
    • Others
      • Table Symptoms of mania associated with HD
  • Geographical segmentation
    • Market segmentation by geography
      • Table Global HD therapeutics market share by geography 2016 and 2021
      • Table Global HD therapeutics market revenue by geography 2016-2021
      • Table Global HD therapeutics market share by geography 2016-2021
      • Table HD therapeutics market scenario in different geographies
    • HD therapeutics market in Americas
      • Table Market scenario in Americas
      • Table HD therapeutics market in Americas 2016-2021 ($ millions)
    • HD therapeutics market in EMEA
      • Table Market scenario in EMEA
      • Table HD therapeutics market in EMEA 2016-2021 ($ millions)
    • HD therapeutics market in APAC
      • Table Market scenario in APAC
      • Table HD therapeutics market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
    • Advances in biomedical sciences
    • Focus on regenerative therapies for mental disorders
      • Table Planned clinical trials of iPS cell-based therapies
    • Rising public interest toward mental health
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global HD therapeutics market 2016
  • Key vendor analysis
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Key highlights
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • H. Lundbeck
      • Table H. Lundbeck: Key highlights
      • Table H. Lundbeck: Strength assessment
      • Table H. Lundbeck: Strategy assessment
      • Table H. Lundbeck: Opportunity assessment
    • Prana Biotechnology
      • Table Prana Biotechnology: Key highlights
      • Table Prana Biotechnology: Strength assessment
      • Table Prana Biotechnology: Strategy assessment
      • Table Prana Biotechnology: Opportunity assessment
    • Teva Pharmaceutical Industries
      • Table Teva Pharmaceuticals: Key highlights
      • Table Teva Pharmaceuticals: Strength assessment
      • Table Teva Pharmaceuticals: Strategy assessment
      • Table Teva Pharmaceuticals: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report